Nvidia among investors in xAI’s $20 bln capital raise- Bloomberg
Investing.com - Guggenheim initiated coverage on Celcuity Inc (NASDAQ:CELC) with a Buy rating and a $110.00 price target on Monday. The stock, which has surged nearly 400% over the past six months and currently trades at $51.88, appears overvalued according to InvestingPro Fair Value metrics.
The research firm cited positive physician feedback on Celcuity’s breast cancer drug gedatolisib, projecting significant sales potential in second-line breast cancer treatment that could drive share appreciation.
Guggenheim forecasts $1.8 billion in U.S. sales for the PIK3CAwt segment alone, from an estimated $3-5 billion total addressable market, and believes the stock has upside potential if peak sales expectations exceed approximately $1.25 billion in this segment.
The firm’s total risk-adjusted forecast, including international markets, second-line PIK3CAm, and first-line sales, reaches $3.4 billion, based on their HR+ breast cancer market model that accounts for current and future competition.
Guggenheim identified upcoming fourth-quarter 2025 data in the PIK3CAm population as a potential catalyst that could move the stock +20%/-35%, but expressed conviction that this trial will succeed and believes the stock could recover next year with the commercial launch even if results disappoint.
In other recent news, Celcuity Inc. has amended its senior secured credit facility with Innovatus Capital Partners, LLC and Oxford Finance LLC, increasing the total term loan facility to $500 million. The agreement includes $350 million in committed capital and up to $150 million at the discretion of both Celcuity and its lenders, with an initial funding of $30 million already received. Additionally, the U.S. Food and Drug Administration (FDA) has accepted Celcuity’s New Drug Application (NDA) for gedatolisib, a treatment for HR+/HER2- advanced breast cancer, for review under the Real-Time Oncology Review program. This development could expedite the FDA’s evaluation process.
Analyst firms have also been active in adjusting their price targets for Celcuity. H.C. Wainwright raised its price target to $66 while maintaining a Buy rating, following the company’s second-quarter financial results and plans to submit an NDA by year-end. Stifel also increased its price target to $68, citing the potential of gedatolisib and the company’s plans to present detailed clinical trial results at a medical congress. Meanwhile, Needham adjusted its price target to $70 from $74, maintaining a Buy rating but expressing concerns about dilution. These developments reflect a range of perspectives on Celcuity’s financial and clinical progress.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.